论文部分内容阅读
目的 :探讨急性髓系白血病中 Evi1基因表达及意义。方法 :应用 RT- PCR方法检测了 94例急性髓系白血病 (AML ,包括初治 4 9例 ,复发 2 3例 ,缓解 2 2例 )患者及 1 0名正常对照 Evi1基因的表达。结果 :1 0名正常人骨髓单个核细胞中无 Evi1 m RNA的表达。AML 患者 Evi1基因总的阳性表达率为 1 8.1 % (1 7/94 ) ,M5型未见表达 ,其中初治、复发、缓解组的 Evi1基因阳性率分别为2 6 .5 %、1 7.4 %、0 ,初治和复发组差别无显著性 (P=0 .5 5 4 )。M3患者中 Evi1、PML /RARα双阳性组与 PML /RARα单阳性组相比复发率高 (P<0 .0 5 ) ,早期死亡率高。 Evi1阳性的 AML患者多数生存期短。结论 :Evi1基因是一个原癌基因 ,在髓系白血病的发病中起重要作用 ,是髓系白血病预后不良的一个指标。
Objective: To investigate the expression of Evi1 gene in acute myeloid leukemia and its significance. Methods: The expression of Evi1 gene in 94 cases of acute myeloid leukemia (AML, including 49 cases of initial treatment, 23 cases of recurrence and 22 cases of remission) and 10 normal controls were detected by RT-PCR. Results: No Evi1 m RNA was expressed in 10 normal human bone marrow mononuclear cells. The total positive expression rate of Evi1 gene in AML patients was 8.11% (17/94) and no expression in M5 cells. The positive rates of Evi1 gene in initial treatment, relapse and remission groups were respectively 26.5% and 7.4% , 0, there was no significant difference between the initial treatment group and the recurrent group (P = 0.545). M3 patients, Evi1, PML / RARα double positive group and PML / RARα single positive group recurrence rate was higher (P <0.05), early mortality was high. Most Evi1-positive AML patients have short survival. Conclusion: The Evi1 gene is a protooncogene that plays an important role in the pathogenesis of myeloid leukemia and is an indicator of the poor prognosis of myeloid leukemia.